Concepedia

Elisabeth Husar

EH

Statistics

Publications

4

Citations

197

H-Index

4

Active since

2017

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

Roche (United States)

Elisabeth Husar is an author at Roche (Switzerland) specializing in immunology, pharmacology, and life sciences.

ORCID

Publications per year

2017–2021

4

Publications

4

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober et al. · mAbs · 2021 · 118 citations · Full text

, , +17

Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab

Nicolas Frances, Marina Bacac, Katharine Bray‐French et al. · Journal of Pharmaceutical Sciences · 2021 · 32 citations

, , +10

Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies

Sven Kronenberg, Elisabeth Husar, Christine M. Schubert et al. · Regulatory Toxicology and Pharmacology · 2017 · 26 citations

, , +16

Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans

Elisabeth Husar, Maria Solonets, Olaf Kuhlmann et al. · Toxicologic Pathology · 2017 · 21 citations · Full text

, , +17

1–4 of 4